SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates

SQZ® AAC Phase 1 Trial Observed Best Overall Response (BOR) of Stable Disease or Better in 60 Percent (3 of 5) of Treated Patients, Including One Patient with a Confirmed Complete ResponseSQZ® eAPC Phase 1/2 Trial Monotherapy Observed BOR of Stable Disease in 40 Percent (8 of 20) of Treated PatientsReduced Workforce...

Related Keywords

Howard Bernstein ,Biotechnologies Company ,Exchange Commission ,Management Team ,Society For Immunotherapy Of Cancer ,Company Annual Report On Form ,Observed Best Overall Response ,Stable Disease ,Treated Patients ,Including One Patient ,Confirmed Complete ,Cost Reduction Initiatives ,Ongoing Operating Expenses While ,Pursues Strategic ,Interim Chief Executive Officer ,Recent Portfolio ,Activating Antigen Carriers ,Annual Meeting ,Enhanced Antigen Presenting Cell ,Cell Squeeze ,Private Securities Litigation Reform Act ,Annual Report ,Consolidated Statements ,